AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cell death selectively in cancer cells. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.
ABTL0812 has completed the recruitment in a phase 2b double-blind placebo-controlled clinical trial in 140 patients with metastatic pancreatic cancer in USA, Spain, France and Israel.
ABTL0812 has completed the recruitment in a phase 2b double-blind placebo-controlled clinical trial in 140 patients with metastatic pancreatic cancer in USA, Spain, France and Israel.
Media Center
23.06.2026
New European Project PHOENIX launches to develop safer treatments for children with high-risk cancer + info
05.06.2025
AbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous non-small cell lung cancer + info
29.12.2020
The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million + info
